secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0001193125-24-026699
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen presents at Guggenheim Healthcare Talks on Feb 8, 2024; no specific facts in filing
--------------------------------------------------------------------------------

- Furnished a corporate presentation under Item 7.01 for the Guggenheim Healthcare Talks Conference on February 8, 2024.
- Presentation titled 'Developing Innovative Medicines to Treat Urothelial Cancers' – text of exhibit does not include detailed updates.
- No financial results, pipeline milestones, or guidance changes disclosed in the filing.
- UroGen's stock ticker is URGN; presentation is for investor audiences only.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524026699/0001193125-24-026699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524026699/d21038d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-026699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer